These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10577982)

  • 1. European regulatory aspects on new medicines targeted at treatment of rheumatoid arthritis.
    Kreutz G
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I92-5. PubMed ID: 10577982
    [No Abstract]   [Full Text] [Related]  

  • 2. New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval.
    Bertele' V; Assisi A; Di Muzio V; Renzo D; Garattini S
    Eur J Clin Pharmacol; 2007 Sep; 63(9):879-89. PubMed ID: 17646975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performing trials in children with rheumatic diseases: comment on the editorial by Lehman.
    Ruperto N; Martini A; Lovell DJ; Giannini EH; ;
    Arthritis Rheum; 2008 Apr; 58(4):1201-2; author reply 1203. PubMed ID: 18383366
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytokine blocker licensed for relief of rheumatoid arthritis symptoms.
    Am J Health Syst Pharm; 2002 Feb; 59(3):225-6. PubMed ID: 11862629
    [No Abstract]   [Full Text] [Related]  

  • 5. [The European Commission approves the use of adalimumab for children ages 4 to 12].
    Avit JB
    Soins Pediatr Pueric; 2012; (267):10. PubMed ID: 22880320
    [No Abstract]   [Full Text] [Related]  

  • 6. NICE and new drugs for rheumatoid arthritis.
    Lancet; 2008 May; 371(9623):1477. PubMed ID: 18456081
    [No Abstract]   [Full Text] [Related]  

  • 7. Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis.
    Smolen JS; Boers M; Abadie EC; Breedveld FC; Emery P; Bardin T; Goel N; Ethgen DJ; Avouac BP; Durez P; Flamion B; Laslop A; Miossec P; Reiter S; Reginster JY;
    Rheumatology (Oxford); 2011 Oct; 50(10):1732-6. PubMed ID: 21242246
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapy with not yet approved drugs or for not yet approved indications].
    Wollenhaupt J
    Z Rheumatol; 2001 Dec; 60(6):450-2. PubMed ID: 11826739
    [No Abstract]   [Full Text] [Related]  

  • 9. Tocilizumab (Actemra) for rheumatoid arthritis.
    Med Lett Drugs Ther; 2010 Jun; 52(1340):47-8. PubMed ID: 20539266
    [No Abstract]   [Full Text] [Related]  

  • 10. Ethical aspects of new medicines targeted at treatment of RA.
    Garcia-Porrúa C; González-Gay MA
    Ann Rheum Dis; 2001 Mar; 60(3):304. PubMed ID: 11245144
    [No Abstract]   [Full Text] [Related]  

  • 11. How many types of patients meet classification criteria?
    Roth SH
    J Rheumatol; 1995 Jul; 22(7):1435; author reply 1435-6. PubMed ID: 7562792
    [No Abstract]   [Full Text] [Related]  

  • 12. [Solutions for off-label therapy].
    Schmidt WA
    Z Rheumatol; 2003; 62(Suppl 2):II54-6. PubMed ID: 14648094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baricitinib (olumiant) for rheumatoid arthritis.
    Med Lett Drugs Ther; 2018 Jul; 60(1551):120-121. PubMed ID: 30036348
    [No Abstract]   [Full Text] [Related]  

  • 14. A future for regulatory science in the European Union: the European Medicines Agency's strategy.
    Hines PA; Janssens R; Gonzalez-Quevedo R; Lambert AIOM; Humphreys AJ
    Nat Rev Drug Discov; 2020 May; 19(5):293-294. PubMed ID: 32235873
    [No Abstract]   [Full Text] [Related]  

  • 15. Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept.
    van Luijn JC; Danz M; Bijlsma JW; Gribnau FW; Leufkens HG
    Scand J Rheumatol; 2011 May; 40(3):183-91. PubMed ID: 20858147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orencia approved for rheumatoid arthritis.
    Health News; 2006 Mar; 12(3):2. PubMed ID: 16535763
    [No Abstract]   [Full Text] [Related]  

  • 17. [Revised recommendations of the Deutsche Gesellschaft für Rheumatologie on therapy with tumor necrosis factor-inhibiting active substances on inflammatory diseases].
    Manger B;
    Z Rheumatol; 2002 Dec; 61(6):694-7. PubMed ID: 12491133
    [No Abstract]   [Full Text] [Related]  

  • 18. Is combination second-line therapy in rheumatoid arthritis more aggressive than helpful?
    Berthelot JM; Saraux A; Maugars Y; Prost A; Le Goff P
    Rev Rhum Engl Ed; 1999 Apr; 66(4):224-8. PubMed ID: 10339779
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice.
    Scheinberg M; Castañeda-Hernández G
    Arthritis Res Ther; 2014 Dec; 16(6):501. PubMed ID: 25677586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant DNA product for rheumatoid arthritis.
    FDA Consum; 2003; 37(2):5. PubMed ID: 12715755
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.